2024-11-14 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Stock Performance and Comparison:**

Eli Lilly and Co (LLY) is a leading pharmaceutical company engaged in the research, development, and manufacturing of pharmaceutical products. 

* **Cumulative Return:** 916.12%
* **S&P 500 (VOO) Cumulative Return:** 179.47%
* **Return Difference:** 736.65%
* **Relative Outperformance:** 77.95% (This indicates that LLY has outperformed the S&P 500 by a significant margin historically, ranking in the top 77.95% of its historical performance relative to the S&P 500.)

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 30.4% | 18.8% | -8.0% | 0.8 | 80.2 |
| 2016-2018  | 50.8% | 18.8% | 18.5% | 0.7 | 109.8 |
| 2017-2019  | 89.5% | 16.8% | 37.8% | 0.7 | 124.8 |
| 2018-2020  | 113.2% | 21.9% | 65.8% | 0.7 | 160.3 |
| 2019-2021  | 154.6% | 21.9% | 54.6% | 0.7 | 262.2 |
| 2020-2022  | 190.4% | 21.9% | 166.8% | 0.7 | 347.3 |
| 2021-2023  | 266.0% | 18.6% | 231.1% | 0.5 | 553.4 |
| 2022-2024  | 207.3% | 19.0% | 176.9% | 0.6 | 777.4 |

* **Alpha:**  Positive alpha indicates that the stock has outperformed its benchmark (S&P 500) after adjusting for market risk. LLY consistently exhibits positive alpha, suggesting strong performance.
* **Beta:** Beta measures the volatility of a stock relative to the market. A beta less than 1 suggests lower volatility than the market, while a beta greater than 1 indicates higher volatility. LLY generally has a beta close to 0.7, indicating lower volatility compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** 811.81
* **5-day Moving Average:** 818.42
* **20-day Moving Average:** 855.65
* **60-day Moving Average:** 898.79

LLY is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a short-term downtrend.

**3. Technical Indicators and Momentum:**

* **RSI:** 31.61 (Below 30 suggests the stock is oversold.)
* **PPO:** -0.31 (Negative PPO indicates a potential downtrend.)
* **Delta_Previous_Relative_Divergence:** -14.56 (This indicates a short-term bearish momentum.)
* **Expected Return:** 116.37% (This signifies a high potential for long-term outperformance compared to the S&P 500, given the historical data and current market conditions.)

**4. Recent Earnings and Outlook:**

| Date        | EPS  | Revenue      |
|--------------|------|---------------|
| 2024-10-30 | 1.08 | $11.44 B |
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2024-10-30 | -0.06 | $9.50 B |

* **Recent Earnings:** The most recent earnings report (2024-10-30) showed an EPS of 1.08 and revenue of $11.44B. While the company missed the analysts' earnings expectations, it exceeded revenue forecasts. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2024-09-30 | $11.44B | 81.02%       |
| 2024-06-30 | $11.30B | 80.80%       |
| 2024-03-31 | $8.77B  | 80.91%       |
| 2023-12-31 | $9.35B  | 80.88%       |
| 2023-09-30 | $9.50B  | 80.42%       |

* **Revenue Growth:**  The company exhibits consistent revenue growth. 
* **Profit Margin:**  LLY maintains a consistently high profit margin, demonstrating strong profitability.

**2) Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|-----------|------------|
| 2024-09-30 | $14.24B  | 6.81%     |
| 2024-06-30 | $13.56B  | 21.88%    |
| 2024-03-31 | $12.81B  | 17.51%    |
| 2023-12-31 | $10.77B  | 20.33%    |
| 2023-09-30 | $11.22B  | -0.51%    |

* **Equity:**  LLY demonstrates sustained growth in shareholder equity. 
* **ROE:** While ROE shows some volatility, it remains largely positive and indicates strong capital utilization.

**6. News and Recent Issues:**

* **Recent Earnings Release:** The most recent earnings release, published on October 30, 2024, reported better than expected revenue but slightly missed earnings estimates.
* **Analyst Opinions:**  Finbold reports that LLY has received a strong consensus rating of "Buy" with a median price target of $875.10. 
* **Market Outlook:**  Several analysts highlight the potential for LLY's pipeline of drugs, particularly in areas like diabetes and obesity, to drive future growth. 
* **Performance Highlights:**  LLY has demonstrated strong historical performance and continues to show consistent revenue growth and profitability.

**7. Overall Analysis:**

LLY is a strong company with a consistent track record of growth and profitability. The stock is currently trading below its moving averages, suggesting a short-term downtrend.  Technical indicators like RSI and PPO suggest the stock might be oversold. However, the company's recent earnings and its promising pipeline, coupled with positive analyst ratings, present a favorable outlook for the long term.  LLY's historical outperformance and strong expected returns make it a potential candidate for a long-term investment portfolio, especially for those seeking exposure to the pharmaceutical industry.

**Disclaimer:** This report is for informational purposes only and should not be considered financial advice. It is essential to conduct thorough research and seek professional advice before making any investment decisions.